Skip to main content
Oncology Nation
A SKIPTA COMMUNITY
Toggle navigation
Sign In
Thank you for visiting Oncology Nation! Please complete your membership today to continue.
Expand +
Username
Password
Log in
Create Account
Forgot Password?
Contact
Not an Oncologist or Hematologist?
Search our other communities.
Saved
Promoted
Mark Fesler
Commented on
Multiple Myeloma Connect
's Post
1 week 3 days
No Action Found
"Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in relapsed/refractory multiple myeloma"
Source :
https://teneobio.com/wp-content/uploads/ASH-TNB-CERodriguez.pdf
16 Views
0 Likes
0 Follows
1 Comment
0 Shares
Mark Fesler
1 week 3 days
This bite antibody is a promising method of targeting BCMA for myeloma with a reasonable balance of efficacy and safety for a heavily pretreated patient population
This bite antibody is a promising method of targeting BCMA for myeloma with a reasonable balance of efficacy and safety for a heavily pretreated patient population